ERBB2 and gastroesophageal junction adenocarcinoma: A retrospective study of 726 GC cases that underwent surgical resection at 4 clinical centers in China reported a HER2-positive rate of 13% [16], while another global multicenter study evaluated 734 patients with G/GEJ adenocarcinoma at 11 Chinese hospitals and found that 12% were HER2-positive [17].